Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial
- PMID: 11438914
- DOI: 10.1086/321864
Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial
Erratum in
- Clin Infect Dis 2001 Sep 1;33(5):749
Abstract
Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.
Comment in
-
Clarithromycin for the treatment of Mediterranean spotted fever.Clin Infect Dis. 2002 Feb 15;34(4):560. doi: 10.1086/338719. Clin Infect Dis. 2002. PMID: 11797192 Clinical Trial. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous

